Gatipotuzumab

CAS No. 1264737-26-9

Gatipotuzumab( —— )

Catalog No. M37170 CAS No. 1264737-26-9

Gatipotuzumab (PankoMab) is a novel humanized monoclonal antibody conjugated to the tumor-associated epitope of mucin 1 (TA-MUC1) with potential anti-tumor activity for the study of recurrent epithelial ovarian cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 421 Get Quote
5MG 686 Get Quote
10MG 1093 Get Quote
25MG 1555 Get Quote
50MG 2107 Get Quote
100MG 2808 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Gatipotuzumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Gatipotuzumab (PankoMab) is a novel humanized monoclonal antibody conjugated to the tumor-associated epitope of mucin 1 (TA-MUC1) with potential anti-tumor activity for the study of recurrent epithelial ovarian cancer.
  • Description
    Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC).
  • In Vitro
    Gatipotuzumab (PankoMab) strongly binds to a short MUC1 peptide of 30 amino acids comprising 1.5 TRs when it is glycosylated with GalNAcα at the T of the PDTRP-sequence, but not if the same peptide is not glycosylated.Gatipotuzumab (PankoMab) (1 h) has a high-affinity towards tumour cells (KD of 0.91, 3.03, 3.84 and 7.14 nM towards NM-D4, ZR75-1, MCF-7 and T-47D, respectively).Gatipotuzumab (PankoMab) (0-5 μg/mL; 4 h) shows specific anti-tumor antibody-dependent cell cytotoxicity activity.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Mucin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1264737-26-9
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Macchini M, et al. Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 gatipotuzumab (GAT) with the anti-EGFR tomuzotuximab (TO) or panitumumab in patients with refractory solid tumors. European Journal of Cancer, 2020, 138: S5-S6.
molnova catalog
related products
  • Gefapixant citrate

    Gefapixant citrate is an orally active P2X3 receptor (P2X3R) antagonist that acts on human homologous recombinant hP2X3 (IC50: ~30 nM) and hP2X2/3 (IC50: 100-200 nM).

  • FKBP12 PROTAC RC32

    FKBP12 PROTAC RC32 is a PROTAC-like degrader targeting FKBP12. It can degrade FKBP12 in organs after intraperitoneal administration.

  • VU 0357121

    VU0357121, a positive allosteric modulator of mGlu5 (EC50: 33 nM), is inactive or very weakly antagonizing at other mGlu receptor subtypes.